Zinplava 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
II/0037 
C.I.6.a - Change(s) to therapeutic indication(s) - 
14/12/2023 
26/01/2024 
SmPC and PL 
Addition of a new therapeutic indication or 
modification of an approved one 
IAIN/0039 
B.II.b.2.c.1 - Change to importer, batch release 
07/12/2023 
26/01/2024 
Annex II and 
arrangements and quality control testing of the FP - 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
PL 
II/0038/G 
This was an application for a group of variations. 
22/06/2023 
26/01/2024 
SmPC, 
Labelling and 
PL 
B.II.e.4.c - Change in shape or dimensions of the 
container or closure (immediate packaging) - Sterile 
medicinal products 
B.II.e.5.c - Change in pack size of the finished 
product - Change in the fill weight/fill volume of 
sterile multidose (or single-dose, partial use) 
parenteral medicinal products, including 
biological/immunological medicinal products 
B.II.b.4.f - Change in the batch size (including batch 
size ranges) of the finished product - The scale for a 
biological/immunological medicinal product is 
increased/decreased without process change (e.g. 
duplication of line) 
PSUSA/10576
Periodic Safety Update EU Single assessment - 
12/05/2023 
n/a 
PRAC Recommendation - maintenance 
/202210 
bezlotoxumab 
IAIN/0035/G 
This was an application for a group of variations. 
18/11/2022 
24/03/2023 
Annex II and 
PL 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
Page 2/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IA/0034 
A.4 - Administrative change - Change in the name 
22/09/2022 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
PSUSA/10576
Periodic Safety Update EU Single assessment - 
10/06/2022 
n/a 
PRAC Recommendation - maintenance 
/202110 
bezlotoxumab 
II/0031 
B.I.b.2.d - Change in test procedure for AS or 
22/04/2022 
n/a 
starting material/reagent/intermediate - Substantial 
change to or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
biological AS 
IA/0033 
A.6 - Administrative change - Change in ATC 
08/04/2022 
24/03/2023 
SmPC 
Code/ATC Vet Code 
IA/0032/G 
This was an application for a group of variations. 
18/02/2022 
n/a 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
Page 3/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
R/0029 
Renewal of the marketing authorisation. 
22/07/2021 
01/09/2021 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II and PL 
the CHMP considered that the benefit-risk balance of 
Zinplava in the approved indication remains favourable and 
therefore recommended the renewal of the marketing 
authorisation with unlimited validity. 
PSUSA/10576
Periodic Safety Update EU Single assessment - 
10/06/2021 
n/a 
PRAC Recommendation - maintenance 
/202010 
bezlotoxumab 
IA/0028 
A.7 - Administrative change - Deletion of 
10/03/2021 
n/a 
manufacturing sites 
IB/0026 
C.I.11.z - Introduction of, or change(s) to, the 
07/01/2021 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
PSUSA/10576
Periodic Safety Update EU Single assessment - 
26/11/2020 
n/a 
PRAC Recommendation - maintenance 
/202004 
bezlotoxumab 
IA/0025 
A.4 - Administrative change - Change in the name 
30/10/2020 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
Page 4/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturer of a novel excipient 
IB/0024 
C.I.z - Changes (Safety/Efficacy) of Human and 
15/09/2020 
01/09/2021 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
II/0022 
B.I.b.2.d - Change in test procedure for AS or 
09/07/2020 
n/a 
starting material/reagent/intermediate - Substantial 
change to or replacement of a 
biological/immunological/immunochemical test 
method or a method using a biological reagent for a 
biological AS 
IB/0021/G 
This was an application for a group of variations. 
18/05/2020 
n/a 
B.I.a.4.z - Change to in-process tests or limits 
applied during the manufacture of the AS - Other 
variation 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
Page 5/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10576
Periodic Safety Update EU Single assessment - 
14/05/2020 
n/a 
PRAC Recommendation - maintenance 
/201910 
bezlotoxumab 
PSUSA/10576
Periodic Safety Update EU Single assessment - 
31/10/2019 
n/a 
PRAC Recommendation - maintenance 
/201904 
bezlotoxumab 
PSUSA/10576
Periodic Safety Update EU Single assessment - 
16/05/2019 
n/a 
PRAC Recommendation - maintenance 
/201810 
bezlotoxumab 
IB/0018 
B.II.g.5.c - Implementation of changes foreseen in 
28/03/2019 
n/a 
an approved change management protocol - For a 
biological/immunological medicinal product 
IB/0017 
B.II.z - Quality change - Finished product - Other 
22/02/2019 
n/a 
variation 
IB/0015/G 
This was an application for a group of variations. 
04/01/2019 
n/a 
B.I.b.2.c - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure for a reagent, which 
does not have a significant effect on the overall 
quality of the AS 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
II/0014 
B.II.g.2 - Introduction of a post approval change 
06/12/2018 
n/a 
management protocol related to the finished product 
Page 6/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
II/0013 
B.I.a.2.c - Changes in the manufacturing process of 
29/11/2018 
n/a 
the AS - The change refers to a [-] substance in the 
manufacture of a biological/immunological substance 
which may have a significant impact on the medicinal 
product and is not related to a protocol 
PSUSA/10576
Periodic Safety Update EU Single assessment - 
31/10/2018 
n/a 
PRAC Recommendation - maintenance 
/201804 
bezlotoxumab 
T/0011 
Transfer of Marketing Authorisation 
23/05/2018 
15/06/2018 
SmPC, 
Labelling and 
PL 
PSUSA/10576
Periodic Safety Update EU Single assessment - 
17/05/2018 
n/a 
PRAC Recommendation - maintenance 
/201710 
bezlotoxumab 
IB/0009 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
21/03/2018 
15/06/2018 
SmPC 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
IB/0008 
B.I.a.2.a - Changes in the manufacturing process of 
28/02/2018 
n/a 
the AS - Minor change in the manufacturing process 
of the AS 
PSUSA/10576
Periodic Safety Update EU Single assessment - 
30/11/2017 
n/a 
PRAC Recommendation - maintenance 
/201704 
bezlotoxumab 
IA/0006 
B.II.e.2.c - Change in the specification parameters 
27/10/2017 
n/a 
and/or limits of the immediate packaging of the 
finished product - Deletion of a non-significant 
specification parameter (e.g. deletion of an obsolete 
Page 7/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
parameter) 
IB/0005 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
18/10/2017 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
IB/0003 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
04/09/2017 
15/06/2018 
SmPC 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
IA/0004/G 
This was an application for a group of variations. 
31/08/2017 
n/a 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.b - Administrative change - Change in the name 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
N/0001 
Minor change in labelling or package leaflet not 
30/03/2017 
15/06/2018 
PL 
connected with the SPC (Art. 61.3 Notification) 
Page 8/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
